Advertisement


Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

2017 Quality Care Symposium

Advertisement

Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).



Related Videos

Issues in Oncology

Greg D. Judy, MD, on Safety Incidents in Radiotherapy

Greg D. Judy, MD, of UNC Health Care, discusses the contributing factors, and possible fixes, for near-miss and actual safety incidents in patients being treated with radiotherapy.

Issues in Oncology

Gabrielle Rocque, MD, on The Oncology Care Model: Transforming Practices

Gabrielle Rocque, MD, of the University of Alabama at Birmingham, discusses the challenges of implementing Oncology Care Model requirements, such as providing treatment plans, and the opportunities to transform practices with improved workflow and patient outcomes.

Issues in Oncology

Gwendolyn P. Quinn, PhD, on Underserved Cancer Patients and Survivors: Are We Listening to Them?

Gwendolyn P. Quinn, PhD, of Moffitt Cancer Center, discusses the challenges that minority, LGBTQ, low-literacy, and underserved populations face in getting their voices heard and what it will take to change that.

Cost of Care
Symptom Management

Laura E. Panattoni, PhD, on Costs of Preventable Emergency Department Use

Laura E. Panattoni, PhD, of the Fred Hutchinson Cancer Research Center, discusses results from a regional study on emergency department costs during cancer treatment and the need to focus on managing symptoms (Abstract 2).

Issues in Oncology
Lung Cancer

Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).

Advertisement

Advertisement




Advertisement